| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Larry Moreland | Q89380794 |
| P2093 | author name string | Aarat M. Patel | |
| P2860 | cites work | Comparison of different biologic agents in patients with rheumatoid arthritis after failure of the first biologic therapy | Q84569891 |
| Cost-effectiveness of biologics as first-line treatment of rheumatoid arthritis: case closed? | Q84834532 | ||
| Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis | Q24235784 | ||
| IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats | Q24294661 | ||
| Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6 | Q24563585 | ||
| Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study | Q24630541 | ||
| Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious | Q24795061 | ||
| Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) | Q28280453 | ||
| Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group | Q29616063 | ||
| Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense | Q30885007 | ||
| Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis | Q33389401 | ||
| Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project | Q33573112 | ||
| Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group | Q33885648 | ||
| Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis | Q33910329 | ||
| Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial | Q33976382 | ||
| Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy tr | Q34027654 | ||
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs | Q34110066 | ||
| Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis | Q34113970 | ||
| Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis | Q34315745 | ||
| Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial | Q34530459 | ||
| Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont | Q34547981 | ||
| Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial | Q34552451 | ||
| Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial | Q34609376 | ||
| The Disease Activity Score and the EULAR response criteria | Q34651201 | ||
| Epidemiology and genetics of rheumatoid arthritis | Q34731244 | ||
| American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. | Q34782898 | ||
| IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial | Q34795777 | ||
| The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo | Q34989826 | ||
| The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. | Q35036985 | ||
| Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed | Q35554130 | ||
| Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab | Q35954629 | ||
| Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibi | Q37089685 | ||
| Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study | Q37172815 | ||
| Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial | Q37172820 | ||
| Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. | Q37321296 | ||
| Prospective new biological therapies for rheumatoid arthritis | Q37425627 | ||
| Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs | Q37707612 | ||
| Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study | Q40377079 | ||
| Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale | Q40678235 | ||
| Interleukin 6 and its receptor in the immune response and hematopoiesis | Q41830530 | ||
| Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis | Q41945874 | ||
| Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks | Q44774931 | ||
| Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial | Q44930010 | ||
| Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation | Q45075936 | ||
| Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. | Q46019776 | ||
| Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial | Q46271720 | ||
| Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders | Q46554712 | ||
| Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial | Q46778815 | ||
| American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis | Q47643186 | ||
| ??? | Q28295371 | ||
| Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe. | Q51768791 | ||
| The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. | Q52037688 | ||
| Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. | Q52221782 | ||
| Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. | Q52850198 | ||
| Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. | Q52855974 | ||
| Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. | Q53239672 | ||
| Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. | Q55049410 | ||
| Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study | Q57751326 | ||
| Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial | Q57752107 | ||
| Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor -independent mouse model | Q58999293 | ||
| The Effect of Glucocorticoids on Joint Destruction in Rheumatoid Arthritis | Q61912636 | ||
| Rheumatoid arthritis | Q68567938 | ||
| Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis | Q72891553 | ||
| A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis | Q73235899 | ||
| Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial | Q73249042 | ||
| Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes | Q74455180 | ||
| Rheumatoid arthritis | Q74541001 | ||
| Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial | Q78667340 | ||
| Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group st | Q79765442 | ||
| Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate | Q80201780 | ||
| Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study | Q80419633 | ||
| Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition | Q81216018 | ||
| Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial | Q81658198 | ||
| Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis | Q81710047 | ||
| Circulating markers of inflammation are related to carotid artery atherosclerosis | Q81721266 | ||
| The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had | Q82132610 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| interleukins | Q194908 | ||
| globulins | Q321710 | ||
| monoclonal antibody | Q422248 | ||
| blood proteins | Q425056 | ||
| tocilizumab | Q425154 | ||
| disease-modifying antirheumatic drug | Q810254 | ||
| interleukin-6 | Q24724988 | ||
| P304 | page(s) | 263-278 | |
| P577 | publication date | 2010-10-01 | |
| P1433 | published in | Drug Design, Development and Therapy | Q2566724 |
| P1476 | title | Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy | |
| Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy | |||
| P478 | volume | 4 |
| Q36241388 | A novel approach to genome-wide association analysis identifies genetic associations with primary biliary cholangitis and primary sclerosing cholangitis in Polish patients. |
| Q84459108 | Acute exposure to 50-Hz magnetic fields increases interleukin-6 in young healthy men |
| Q64355353 | Association of Interleukin 6 Receptor Variant With Cardiovascular Disease Effects of Interleukin 6 Receptor Blocking Therapy: A Phenome-Wide Association Study |
| Q37959331 | Cellular and molecular mechanisms of autoimmune disease |
| Q38994619 | Chemopreventive effects of a curcumin-like diarylpentanoid [2,6-bis(2,5-dimethoxybenzylidene)cyclohexanone] in cellular targets of rheumatoid arthritis in vitro. |
| Q85963569 | Clinical and ultrasound evaluation of the response to tocilizumab treatment in patients with rheumatoid arthritis: a case series |
| Q42254666 | Does tocilizumab contribute to elevation of rheumatoid factor and induction of paradoxical syaloadenitis in rheumatoid arthritis patients? |
| Q37208456 | Dosing of Intravenous Tocilizumab in a Real-World Setting of Rheumatoid Arthritis: Analyses from the Corrona Registry |
| Q35352554 | Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study |
| Q35774189 | Endothelial progenitor cells in cardiovascular disease and chronic inflammation: from biomarker to therapeutic agent |
| Q27016197 | Host Responses in the Link Between Periodontitis and Rheumatoid Arthritis |
| Q37983096 | IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential |
| Q35859326 | IL-6 trans-signaling increases expression of airways disease genes in airway smooth muscle |
| Q29417065 | Identification of IL6R and chromosome 11q13.5 as risk loci for asthma |
| Q33921579 | Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy |
| Q36679769 | Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis |
| Q35952745 | Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers |
| Q37947514 | Interleukin-23 as a potential therapeutic target for rheumatoid arthritis |
| Q37997359 | Interleukin-6 and cytochrome-P450, reason for concern? |
| Q38089303 | Mast cells: a new target in the treatment of complex regional pain syndrome? |
| Q45101917 | Nodular progression of lentigo malignant melanoma during a treatment with tocilizumab: cause or coincidence? |
| Q37388213 | Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis |
| Q54519453 | Norisoboldine inhibits the production of interleukin-6 in fibroblast-like synoviocytes from adjuvant arthritis rats through PKC/MAPK/NF-κB-p65/CREB pathways. |
| Q53176613 | Ocular surface findings in patients with rheumatoid arthritis under methotrexate or biological agent therapy. |
| Q47153616 | Periodontal, salivary and IL-6 status in rheumatoid arthritis patients. A cross-sectional study |
| Q86934393 | Reduced dose of tocilizumab for the maintenance of remission in patients with rheumatoid arthritis: a clinical experience |
| Q34627012 | Review of Systemic Immunosuppression for Autoimmune Uveitis |
| Q38234629 | Rituximab and tocilizumab for the treatment of rheumatoid arthritis |
| Q37936459 | Road to remission: a comprehensive review of therapy in uveitis |
| Q42578542 | Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis |
| Q36412824 | Serum Levels of IL-6 and TNF-α May Correlate with Activity and Severity of Rheumatoid Arthritis |
| Q39599075 | Severe Pulmonary Suppuration with Infection-Induced Systemic Inflammatory Response Syndrome following Tongue Cancer Surgery in a Patient Undergoing Tocilizumab Therapy for Rheumatoid Arthritis. |
| Q39043565 | Severe sepsis caused by Aeromonas hydrophila in a patient using tocilizumab: a case report |
| Q28076558 | Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date |
| Q40110959 | Th17 response and inflammatory autoimmune diseases |
| Q49901596 | Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve and Experienced Patients |
Search more.